Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials

BACKGROUND: In three 8-week studies of vilazodone 40 mg/d (NCT00285376, NCT00683592, and NCT01473394) and a 10-week study of vilazodone 20 or 40 mg/d (NCT01473381), adults with major depressive disorder (MDD) showed significantly greater improvement with vilazodone versus placebo in global disease s...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgam, Suresh, Chen, Changzheng, Gommoll, Carl P, Edwards, John, Citrome, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144912/
https://www.ncbi.nlm.nih.gov/pubmed/27980409
http://dx.doi.org/10.2147/NDT.S117581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144912/
https://www.ncbi.nlm.nih.gov/pubmed/27980409
http://dx.doi.org/10.2147/NDT.S117581

Ejemplares similares